Search
Buformin
go.drugbank.com/drugs/DB04830ApprovedWithdrawnIt was withdrawn from the market in most countries due to a high risk of causing lactic acidosis. … Buformin is an anti-diabetic drug of the biguanide class, chemically related to metformin and phenformin.
Categories: Drugs Used in DiabetesmRNA-1345
go.drugbank.com/drugs/DB18739ApprovedInvestigationalmRNA-1345 is a nucleoside modified mRNA encoding the F-glycoprotein from RSV subtype A stabilized in its prefusion conformation.[L53393] It is the primary ingredient of the RSV vaccine mRESVIA. … mRESVIA was first approved in the EU and US in 2024 for use in patients 60 years of age and older.
Maralixibat
go.drugbank.com/drugs/DB16226ApprovedInvestigational[A239249] No clinical trials have been performed to assess the efficacy of these treatments for cholestatic pruritus and treatments were given based on a prescriber's clinical experience. … with Alagille syndrome:[L43547] it was granted marketing authorization in Europe on 13 December 2022.
Caplacizumab
go.drugbank.com/drugs/DB06081ApprovedInvestigationalCaplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019,[L5302] and approved previously by the EU in October 2018 as a combination therapy with plasma exchange and immunosuppression … [A174634]In December 2025, the FDA expanded this indication to include pediatric patients aged 12 years and older with aTTP, in the same combination regimen.[L54958,L54963]
Polidocanol
go.drugbank.com/drugs/DB06811ApprovedInvestigationalPolidocanol is a sclerosing agent indicated to treat uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower … The formula for Polidocanol has the structural formula C12H25(OCH2CH2)nOH, a mean extent of polymerization (n) of approximately 9 and a mean molecular weight of approximately 600.
Categories: Compounds used in a research, industrial, or household settingSamidorphan
go.drugbank.com/drugs/DB12543ApprovedInvestigational, and a longer half-life, making it an attractive candidate for oral dosing. … [A235638, A235643] Samidorphan was first approved as a variety of fixed-dose combination tablets with [olanzapine] by the FDA on May 28, 2021, and is currently marketed under the trademark LYBALVI™
Salts: Samidorphan L-malateTralokinumab
go.drugbank.com/drugs/DB12169ApprovedInvestigationalUS in December 2021. … Tralokinumab was first approved for the treatment of atopic dermatitis by the EMA in June 2021, under the brand name Adtralza (Leo Pharma), and was subsequently approved in Canada in October 2021 and the
Avatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[F95] Avatrombopag was first approved by the FDA in May 2018 for use in adults with chronic liver disease who are scheduled to undergo a procedure. … [A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy.
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. … Formestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity.
Synonyms: 4-OH-ATezepelumab
go.drugbank.com/drugs/DB15090ApprovedInvestigational[A243764, A243769] Thymic stromal lymphopoietin (TSLP), an innate pleiotropic IL-2-family cytokine, has emerged as a key upstream regulator of chronic inflammation across asthma endotypes. … [A243764, A243769, A243774] Tezepelumab is a human monoclonal IgG2λ antibody directed against TSLP produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.